Karen M. Olsson, Jan Fuge, Da-Hee Park, Jan C. Kamp, Dominik Berliner, Constantin von Kaisenberg, Marius M. Hoeper
European Respiratory Journal 2024; DOI: 10.1183/13993003.00179-2024 

Extract

For many years, women diagnosed with pulmonary arterial hypertension (PAH) received advice against pregnancy due to a significant mortality risk [1, 2]. With therapeutic advancements, pregnancies in women with PAH continue to be associated with heightened risks, although uncomplicated pregnancies are increasingly being reported, particularly in women with well-controlled disease [3–6]. The 2022 European pulmonary hypertension guidelines mirror these advancements, no longer generally discouraging pregnancy but recommending an individualized approach with shared decision-making for women with PAH contemplating or experiencing pregnancy [7, 8].